The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency (NCT04069546) | Clinical Trial Compass
CompletedNot Applicable
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
China46 participantsStarted 2019-09-07
Plain-language summary
to detect the effects of RIC on stroke-induced immunodeficiency and inflammation response in acute ischemic stroke patients
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age≥18 years old;
* Confirmed diagnosis of acute ischemic stroke(AIS) with onset of symptoms within 48h at recruitment;
* NIHSS score: ≤15;
* Prestroke modified Rankin Scale(mRS) ≤2;
* subject or his or her legally authorized representative was able to provide informed consent.
Exclusion Criteria:
* uncontrolled hypertension (defined as systolic blood pressure ≥200 mmHg);
* participation in another device or drug trial simultaneously;
* any vascular, soft tissue, or orthopedic injury (eg, superficial wounds and fractures of the arm) that contraindicated unilateral arm ischemic preconditioning;
* peripheral vascular disease (especially subclavian arterial and upper limb artery stenosis or occlusion);
* Women who have a positive pregnancy test;
* History of malignancies;
* Using remote ischemic conditioning within the preceding 1 week;
* known infection at admission;
* a history of infection or the use of antibiotics, immunosuppressants, or steroids within the preceding 3 months.
* Other conditions are not suitable for this trial (evaluated by researchers)
What they're measuring
1
The changes of mHLA-DR level in plasma
Timeframe: change from baseline to 2(±24h)days, and at 7(±24h)days after admission